Drug Profile
MP 15
Latest Information Update: 23 Apr 1997
Price :
$50
*
At a glance
- Originator Hazleton Wisconsin
- Class Antiarrhythmics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arrhythmias
Most Recent Events
- 23 Apr 1997 No-Development-Reported for Arrhythmias in USA (Unknown route)
- 17 Mar 1995 Preclinical development for Arrhythmias in USA (Unknown route)